Skip to main content
. 2017 Oct 11;27(2):211–223. doi: 10.1093/hmg/ddx366

Figure 7.

Figure 7.

Removal of the neomycin cassette from the Velocigene Trem2 knockout mice ameliorates aberrant Treml1 expression. (A) Schematic of Trem2−/− (Velocigene) male mice crossed with EIIA-Cre mice to remove the floxed neomycin cassette driven by the human Ubiquitin C promoter. The first cross of EIIA-Cre to Trem2−/− (Velocigene) mice creates a mosaic of neomycin deletion due to some inefficiencies in Cre activity at early embryonic stages. (B) RT-qPCR for Treml1 levels in hippocampal tissue from EIIA-Cre+/− Trem2+/− mice that were negative for neomycin, were compared with WT, Trem2+/−, and Trem2−/− Velocigene controls. EIIA-Cre+/− Trem2+/− mice that were negative for neomycin had significantly decreased levels of Treml1 relative to both Trem2+/−, and Trem2−/− Velocigene controls and were similar to WT. Shown are the averages ± S.E.M from N = 3–5 animals per group (One-way ANOVA, Tukey posthoc, *P <0.05, ****P≤ 0.0001). (C) RT-qPCR for Treml1 and neomycin levels in hippocampal tissue from EIIA Cre+/− Trem2+/− mice over a range of mosaicism was conducted. A highly significant, positive correlation between Treml1 and neomycin expression was observed. Shown is the correlation from N = 18 animals ranging in neomycin expression. (Linear regression, R2=0.9879, P < 0.0001).